Pemvidutide IMPACT Results: 59% MASH Resolution in Phase 2 Trial
Altimmune reports pemvidutide achieved 59% MASH resolution without fibrosis worsening in the IMPACT trial, positioning the GLP-1/glucagon dual agonist as a potential breakthrough for liver disease.
Altimmune has reported striking results from the IMPACT phase 2 trial evaluating pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and liver fibrosis. The dual GLP-1/glucagon receptor agonist achieved MASH resolution without fibrosis worsening in 59% of participants, significantly exceeding placebo and potentially establishing a new efficacy benchmark for this indication.
What We Know
The IMPACT trial enrolled adults with biopsy-confirmed MASH and stage F2 or F3 liver fibrosis, representing a population with significant disease burden and elevated risk of progression to cirrhosis. Participants received weekly subcutaneous injections of pemvidutide at various dose levels or placebo for 48 weeks [impact-trial-results].
At the primary efficacy analysis, the highest dose of pemvidutide demonstrated:
- 59% MASH resolution without worsening of fibrosis, compared to 17% with placebo
- 43% achieved fibrosis improvement by at least one stage without MASH worsening
- Significant reductions in liver fat content as measured by MRI-PDFF (proton density fat fraction)
- Improvements in liver enzyme levels including ALT and AST
These results compare favorably to other agents in development for MASH, including the recently approved resmetirom (Rezdiffra), which achieved approximately 30% MASH resolution in its pivotal trials [altimmune-press].
The Dual Agonist Mechanism
Pemvidutide activates both GLP-1 and glucagon receptors, a combination that may offer particular advantages for liver disease [gcg-liver-mechanism]. Understanding why requires examining what each receptor contributes:
GLP-1 receptor activation promotes weight loss and metabolic improvement through appetite suppression, enhanced insulin secretion, and various tissue-specific effects. GLP-1 agonists like semaglutide have demonstrated benefit in MASH trials, though their effects on fibrosis have been more modest than their impact on steatohepatitis.
Glucagon receptor activation directly stimulates hepatic fatty acid oxidation and promotes the clearance of fat from liver cells. This hepatocentric mechanism may explain why dual agonists appear to achieve more pronounced effects on liver fat compared to GLP-1 agonists alone.
The combination appears to provide complementary effects: GLP-1 activity improves systemic metabolic health and promotes weight loss, while glucagon activity directly addresses hepatic lipid accumulation. In the IMPACT trial, participants experienced substantial weight loss alongside liver-specific improvements, though the relative contribution of each mechanism remains under investigation.
Weight Loss and Metabolic Effects
Participants in the IMPACT trial receiving the highest pemvidutide dose lost approximately 11-14% of body weight over 48 weeks, consistent with the drug’s dual agonist profile. Associated metabolic improvements included:
- Reductions in HbA1c in participants with type 2 diabetes or prediabetes
- Improvements in lipid profiles
- Decreases in blood pressure
- Reductions in inflammatory markers
These systemic effects likely contribute to liver outcomes beyond the direct hepatic actions of glucagon receptor activation.
What We Don’t Know
Despite the promising results, several important questions remain before pemvidutide can be considered a proven treatment for MASH.
Phase 3 confirmation required: The IMPACT trial, while well-designed, represents phase 2 data with relatively limited participant numbers. Phase 3 trials with larger populations and longer duration will be necessary to confirm efficacy, characterize safety, and support regulatory approval. Altimmune has announced plans to initiate phase 3 development.
Long-term outcomes: The 48-week treatment period, while adequate for regulatory endpoints based on histological improvement, does not demonstrate whether pemvidutide prevents clinically meaningful outcomes like progression to cirrhosis, hepatocellular carcinoma, liver transplantation, or liver-related mortality. Demonstrating impact on these hard endpoints would require much longer trials.
Durability of response: What happens after treatment discontinuation remains unclear. Whether the liver improvements persist, partially reverse, or completely reverse off therapy has implications for how the drug would be used clinically.
Safety Considerations
The tolerability profile observed in IMPACT reflected the gastrointestinal effects characteristic of GLP-1 agonists. Nausea and other GI symptoms were common, particularly during dose escalation, though most were mild to moderate and diminished over time.
A theoretical concern with glucagon receptor agonism relates to effects on glucose metabolism, as glucagon raises blood glucose. In practice, the concurrent GLP-1 activity appears to offset this effect, and pemvidutide did not worsen glycemic control in trial participants. However, longer-term safety data in diabetic populations will be important.
Additionally, the substantial weight loss observed raises questions about body composition changes and whether lean mass preservation is adequate. Some GLP-1 agonists have faced scrutiny regarding muscle loss, and this will likely be an area of continued evaluation for pemvidutide.
How Strong Is the Evidence?
The evidence from the IMPACT trial qualifies as suggestive rather than definitive. The trial was randomized, placebo-controlled, and used gold-standard histological endpoints including paired liver biopsies. The results achieved statistical significance with effect sizes that appear clinically meaningful [impact-trial-results].
However, several factors warrant caution:
Phase 2 limitations: The trial enrolled approximately 200 participants, providing reasonable statistical power but limited ability to detect rare adverse events or understand outcomes in subpopulations.
Single trial: Replication in independent studies will strengthen confidence in the findings. The history of MASH drug development includes multiple agents that showed promise in phase 2 but failed in larger trials.
Surrogate endpoints: The FDA has accepted MASH resolution and fibrosis improvement as basis for accelerated approval, but these remain surrogate endpoints. The ultimate measure of a MASH treatment is prevention of liver-related clinical events.
Histological variability: Liver biopsies are subject to sampling variability, and pathologist interpretation of MASH can vary. While the trial used central pathology reading to minimize this issue, it remains an inherent limitation of histological endpoints.
The evidence is strong enough to justify continued development and generate considerable scientific interest, but not yet sufficient to establish pemvidutide as a proven treatment for MASH.
What’s Next
The positive IMPACT results set the stage for several important developments.
Phase 3 planning: Altimmune will design phase 3 trials based on the IMPACT learnings, selecting optimal doses and refining patient selection criteria. These larger trials will need to confirm efficacy while generating the safety database required for regulatory approval.
Competitive landscape: Pemvidutide enters an increasingly competitive field. Resmetirom received FDA approval in 2024 as the first MASH treatment. Multiple GLP-1 agonists, including semaglutide and tirzepatide, are being studied in MASH. Survodutide, another GLP-1/glucagon dual agonist from Boehringer Ingelheim and Zealand Pharma, has reported its own positive MASH trial results.
Combination approaches: Whether pemvidutide might be combined with other agents, such as resmetirom, which has a complementary mechanism targeting thyroid hormone receptor beta, represents an area of potential investigation.
Broader metabolic disease: Pemvidutide’s effects on weight and metabolic parameters suggest potential applications beyond MASH. The compound is also being studied for obesity without liver disease, and the dual agonist mechanism may offer advantages in certain metabolic contexts [hepatology-mash].
Regulatory pathway: The FDA’s acceptance of accelerated approval based on histological endpoints for MASH treatments provides a potential path to market before long-term outcome data mature, though confirmatory trials demonstrating clinical benefit would likely be required post-approval.
The IMPACT results represent meaningful progress in addressing MASH, a condition affecting millions globally for which treatment options remain limited. Whether pemvidutide fulfills its apparent promise will depend on successful phase 3 development and, ultimately, demonstration of benefit in clinical practice.
This information is provided for educational purposes only and does not constitute medical advice. Patients with liver disease should consult hepatology specialists for guidance on their care.
Sources & Citations
- 1
- 2
- 3
- 4
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.